Aastrom's heart failure drug enters midstage development

04/8/2013 | Pharmaceutical Business Review Online

Aastrom Biosciences has started recruiting patients for a Phase IIb trial that will assess the safety and efficacy of its experimental drug Ixmyelocel-T in people with advanced heart failure due to ischemic dilated cardiomyopathy. The randomized, double-blind trial will involve 108 patients.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT